Searle Company Strengthens Its Market Position with 29% Revenue Growth in 2026

The Searle Company Limited has reported a year of significant business progress in its 2026 Annual Report, highlighting strong revenue growth, improved operating performance, lower financing costs and continued investment in pharmaceutical innovation. Despite cost pressures and supply-chain challenges facing the pharmaceutical industry, the company strengthened its core business and expanded its presence in specialised therapies and international markets.

For the financial year ended June 30, 2026, Searle Group recorded consolidated revenue of approximately PKR 36.81 billion, representing an increase of 29% compared with the previous year. Gross profit increased to PKR 19.14 billion, while the gross profit margin improved to 51.98%, up from 49.20% in FY2025. These results reflect improved product availability, more efficient supply-chain management and focused commercial execution.

Improved Financial Performance and Cost Management

One of the major highlights of FY2026 was the improvement in operating profitability. The Group’s profit from operations rose by 43% to PKR 5.29 billion, compared with PKR 3.69 billion in the previous financial year. At the same time, finance costs declined by 48% to approximately PKR 1.09 billion, supported by better working capital management and the rationalisation of borrowings.

These improvements demonstrate the importance of financial discipline and operational efficiency in a competitive pharmaceutical market. While rising input costs, international freight uncertainty and geopolitical developments continued to create challenges, Searle maintained its focus on manufacturing capabilities, product availability and business resilience.

The company also reported continued investment in future growth, balancing financial performance with efforts to strengthen its product portfolio and operating capabilities.

Expanding the Pharmaceutical Portfolio Through Innovation

Product development remained a key priority during the year. Searle introduced new treatment options and strengthened its presence in specialised therapeutic categories.

A major milestone was the launch of Rexeva, a denosumab biosimilar. According to the company’s annual report, it represented the first biosimilar approved in Pakistan and strengthened Searle’s biotechnology portfolio, with relevance to osteoporosis and oncology care.

The company also launched Xavy, containing tirzepatide, expanding its presence in metabolic therapies. Other launches and initiatives highlighted in the report included Semavi in the GLP-1 category, Valmera for neuropathic pain management and Injecfer, an iron-replenishment treatment.

These developments reflect Searle’s broader strategy of introducing differentiated treatment options while supporting scientific engagement with healthcare professionals. The company also participated in medical education programmes and specialist workshops designed to strengthen clinical knowledge and practical capabilities.

Strengthening International Presence

Searle continued to develop its international business during FY2026, with operations and commercial engagement spanning more than 22 countries. Through its Global Business Division, the company worked with distributors, healthcare professionals and regulatory authorities across international markets.

Its participation in scientific conferences, medical forums and professional gatherings supported collaboration with healthcare communities in markets including Sri Lanka, Myanmar, Cambodia, Kenya and Uganda.

The company also received recognition for its export performance at the Pharma Export Summit & Awards in Islamabad in September 2025. These activities demonstrate the role of international partnerships and scientific exchange in supporting Searle’s broader growth ambitions.

Investment in People, Technology and Corporate Responsibility

Beyond financial results, Searle continued to invest in employee development, workplace culture and community engagement. The annual report highlights approximately 33,000 training hours delivered during FY2026, supporting learning and capability building across the organisation.

The company also promoted health awareness through initiatives addressing obesity, blood pressure, diabetes and cholesterol. Community activities, including blood donation initiatives, reflected its stated commitment to healthcare awareness and social responsibility.

Digital transformation was another important area of focus. Through its OneThunder programme, Searle worked to improve the integration and accessibility of business information. Dedicated sales, supply-chain and distribution dashboards were introduced to strengthen performance monitoring and support more informed decision-making.

A Strategic Focus on Sustainable Growth

During the year, Searle transferred its biological medicines and associated brands, together with relevant marketing authorisation rights, to its indirect subsidiary, Searle Biopharma (Private) Limited. The transaction became effective on June 15, 2026, and was intended to provide a more specialised structure for developing the biological medicines portfolio.

The report also acknowledges challenges in businesses outside the core pharmaceutical operations, including an impairment charge related to investments in subsidiaries. This highlights the importance of continued performance reviews and disciplined capital allocation as the Group pursues its long-term strategy.

Looking ahead, the company’s stated priorities include strengthening its core pharmaceutical business, accelerating innovation, expanding its product portfolio and improving operational excellence. Its performance in FY2026 provides a stronger operating foundation, although sustaining growth will depend on execution, market conditions and continued attention to costs and product availability.

Conclusion

The Searle Company Limited’s FY2026 Annual Report presents a picture of stronger revenue, improved margins, lower financing costs and continued investment in pharmaceutical innovation. Its expansion into specialised therapies, international engagement, employee development and digital transformation reflects a strategy that combines commercial growth with healthcare-focused initiatives.

As the company moves into its next phase, maintaining operational efficiency, developing differentiated products and strengthening access to healthcare solutions will remain important to its long-term ambitions. The results of FY2026 mark meaningful progress while also underscoring the need for disciplined execution in a changing pharmaceutical market.